Annexon is a clinical-stage biopharmaceutical company developing medicines that block C1q, the initiating molecule of the classical complement pathway. Its pipeline targets complement-driven autoimmune, neurodegenerative and ophthalmic diseases, including programs in Guillain-Barré syndrome and geographic atrophy. With little or no commercial product revenue, the company focuses on advancing these late-stage candidates for patients with serious neuroinflammatory conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -51 | — |
| Q3 2025 | 0 | — | -54.9 | — |
| Q4 2025 | 0 | — | -46.4 | — |
| Q1 2026 | 0 | — | -44.1 | — |
| Q2 2026 | 0 | — | -55.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Village Super Market, Inc. (VLGEA), Design Therapeutics, Inc. (DSGN), Capital Bancorp, Inc. (CBNK), Priority Technology Holdings, Inc. (PRTH), Hingham Institution for Savings (HIFS), Gyre Therapeutics, Inc. (GYRE)